<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 292 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page291.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=292">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 292 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 292</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=292"><img src="../thumb/292.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.10                                                        2020-04 / 255
       ponatraem., hyperkalaem., hypophosphataem., anorex., insomn.,   Side effects: Freq: Headache, N&V, abdom.pain, diarrh., flatul.,   NYSTACID, (Aspen Pharmacare: Consumer) Pharmacare [P/S]
       anx., confus., somnol., trem., dizzin., dysgeus., tachycard., palpitats.,   hepatotox., rash. Less freq: Leucopen., neutropen., agranulocytos.,   Nystatin
       bradycard., hypotens., hypertens., flush., dyspn., dyspeps., constip.,   trombocytopen., dizzin., vertigo, seiz., insomn., nervousn., fatig., rigors,   Indications: Candidal infects.of oral cavity.
       hepat.fail., inc. gammaglutamyltransfer., jaund., cholestas., hepato-  malaise, hyperkines., hypokalaem., hypercholesterolaem., hypertri-  (S2) SUSP. R/20.1.7/316. 100 000 u/ml.
       meg., hepatit., urticar., prurit., eryth., incr. bld. creatin., incr.bld.urea,   glyceridaem., taste pervers., dyspeps., thirst, fem.sex.dysfunct., in-  835285-006: 20 ml, R37,36
       aggravat.ren.fail., inj. site thrombos./pain, infus.site inflammat.,   termenstr.bleed., menorrhag., leukorrh., polyur., hepat.fail., hepatit.,   Dosage: Adults & childr: 1-2 ml 4xdly, may be incr.to 4-6 ml 4xdly.
       periph. oed. Rare: Haemolyt.anaem., haemolys. Unknown: Dis-  hepatocellul. necros., jaund., hyperton., abnorm. vis., alopec., urticar.,   for sev.infects. Infts: 1-2 ml 4xdly. Newborn prophylax: 1 ml dly.
       semin.IV coagulat., shock; hepatocell. damage incl.fatal., tox.skin   dry skin, abnorm.odour, exfoliat. cutan.reacts.incl.Stev.-Johns.syndr./  Side-effects: N&V, diarrh.
       erupt., eryth. multiforme, Stev.-John.syndr., tox.epiderm. necrolys.,   tox. epiderm.necrolys., anaphylax., flush.
       ren.impairm./ac.ren.fail.     Warnings and special precautions: Monit.pts. develop.abnorm.  SPORANOX, Janssen Pharmaceutica [P/S]
       Warnings and special precautions:. Consid. potent. risk for   liv.funct.for more ser.hepat.injur., discont. ther.when S&S consist.  Itraconazole.
       develop.liv.tumours bef.use, use only if other antifung.not appro-  with liv.dis./ bullous les./erythema multiform.devel., AIDS pts. more   Indications: Reduc.incid.of ac./recurr.persist. vulvovag.candidias.&
       pr., monit.liv.fuct. careful. dur.treatm., early discontinuat.recomm.  prone to develop. sev.cutan.reacts., monit. prothromb. time with   prophylax.thereof when not respond.to convent.ther., persist.vul-
       in pres. of signif.& persist. ALT/AST elev.to minimise risk of adapt.  concom.warfar., monit.bld. gluc. with sulfonylur., poss.phenytoin   vovag. candidias. & dermatomycos.not respond.to convent. ther.,
       regenerat.& potential.subseq.liv. tumour format., conduct treatm.  toxic., monit. theophyll./ciclospor.conc., avoid concom. astemizole,   although proof of effic.limit.it has been used in fung.keratit./syst.
       on risk/benef. basis partic.in sev.liv.funct.impairm./chron.liv.dis.   incr.uveit.risk with concom.rifabutin, concom. zivodine/midazolam/  aspergillos./ candidias./histoplasmos./sporotrichos./ paracocidioi-
       known to repres.preneoplast.condits./pts.receiv. concom. ther.  triazolam, monit. pts.with concom.nevirapine., monit.concom. ter-  do-mycos.& blastomycos, onychomycos. caus.by yeasts &/derma-
       incl.hepatotox.&/genotox.propert., sev. hepat.insuffic., limit.ex-  fenadine if co-admin.(&lt; 400mg fluconazole) consid. essential, pass.  tophytes not respond.to other.ther.
       per.in pts.&lt; 2 yrs., paed. pts. &lt;1 yr.poss.more prone to liv.injur.,   into breast milk, poss. congenit.malformat.in pregn., ren.funct.im-  (S4) CAPS, [P/S] W/20.2.2/43.
       discont. & admin.appropr.treatm.if anaphylact. reacts. incl.shock   pairm., monit. liv.funct.per.in contin.ther.long.than 1 mnth./ if S&S   786433-004: 100 mg, 4, R248,86
       occur., monit.pts.closely if rash dev. & discontin.if les.progress.,   of liv.dysfunct.devel., pts.with underly. dis.incl.AIDS/malign., AIDS   786322-039: 100 mg, 14, R871,08
       monit.pts.with clinic./ laborat.evid.of haemolys closely for evid.  pts.with cryptococc. meningit./recurr.oropharyng. candidias. requir.  786322-020: 100 mg, 28, R1 742,11
       of worsen. & eval.risk/benef.of cont.ther., monit.pts for worsen.  maint.ther.to prev.relapse.  Dosage: Admin.immed.aft.meal. Use in childr.bel. 12 yrs.& elderly
       of ren.funct., incid.of some adverse reacts. high.in paeds.than in   Interactions: Incr.plasma conc.of meds.metabol. by cytochrome   not systemat.stud. Eliminat.slow. from skin & nail. Optim.clinic.
       adults., male fertility potent. affect., reproduct.& testicul.toxic.in   P-450 syst., prolongs prothromb. time in warfarin ther., plasma conc.  mycolog.eff.reach.1-4 wks aft. treatm.cessat for skin infects.& 6-9
       anim. stud., lact. intol. monit.for sirolimus toxicit.with concom.   of sulphonylur. hypoglycaem. incr., incr.phenytoin/zidovudine plasma   mnths for nail infects.
       admin & adjust.dos.if req.    conc., decr.theophyll.clear.& incr.conc./ poss. toxic., interact.with   Ac.& recurr.vulvovag.candidias: 200 mg morn. & even. x1day
       Drug interactions: Incr.AUC of concom. itraconaz. / sirolimus &   astemizole, incr. cisapride conc.with poss.incr.life-threat. card. ar-  OR 200 mg once dly.x3 days.  st
       nifedipine.                   rhythm.risk, clinic.signif.ciclospor.ser.conc.incr., rifabutin/tacrolimus   Reduc.recurr.vag.candidias.incid: 200 mg on 1  day of men-
       See also MDR page 208.        conc.incr., incr.midazolam & triazolam ser.conc.esp.aft.oral fluconaz.  strual cycle x6 mnths.
                                     admin., incr. plasma conc.with hydrochlorothiaz., decr. conc. with ri-  Dermatomycos: 200 mg dly.x7 days, OR 100 mg dly.x15 days.
       MYCOREST, Zydus [P/S]         fampicin, nevirapine expos.incr.by approx.100%.  Tinea pedis & manus: 200 mg 2xdly.x7 days or 100 mg dly.
       Fluconazole                                                x30 days.
       Indications: Adults: Cryptococ.meningit.in ment. alert pts.without   MYLAN TERBINAFINE, (Mylan) Xixia [P/S]  Fung.keratit: 200 mg once dly.x21 days.accord.to clinic.respons.
       local.neurologic.signs & follow-up ther.aft.amphotericin B ther., maint.  Terbinafine HCl.  Onychomycos: Confirm.diagn.from appropr.nail specimens bef.init.
       ther.to prev. cryptococ.dis.relapse in AIDS pts., system. candidias.,   Indications: Fung.skin infect.caus.by Trichophyton, Microsporum   treatm. Continuous treatm: 200 mg dly. x3 mnths. Pulse treatm:
       oropharyng.& oesophag.candidias., fung. infect.prophylax.in pts.  canis & Epidermophyton, ringworm where oral ther. appropr. due to   200 mg 2xdly.x 1 wk. Pulse treatm.are separat.by 3 wk. drug-free
       receiv.chemo and/or radiother., ac./recurr.vag.candidias.& prophy-  site/sev.of infect., onychomycos.  interv. Fingernail infects: 2 pulse treatm. Toe nail infects.with/
       lax.to reduc.recurr.infect.incid., candid.balanit., dermatomycos. incl.  (S4) TABS, A38/20.2.2/0691  without fingernail involvem: 3 pulse treatm.
       tinea corpor./tinea cruris/tinea pedis/tinea unguium (onychomycos.)   705114-001: 250 mg, 14, R306,56  Aspergillos: 200 mg once dly. x2-5 mnths.
       & derm. candida infects.      Dosage: 250 mg once dly.     Candidas.(excl.vulvovag.): 100-200 mg once dly. x3 wks.-7 mnths.
       Childr: Cryptococ.meningit.in ment.alert pts. without local.neurologic.  Treatm.durat.varies accord.to indicat.& sev. Tinea pedis: 2-6 wks.   Incr.dos.to 200 mg 2xdly for invasive/ disseminat.dis.
       signs & follow-up ther.aft. amphotericin B ther., maint.ther.to prev.  Tinea corporis: 4 wks., Tinea cruris: 2-4 wks. Onychomycos: 6   Histoplasmos.(excl.meningeal): 200 mg once dly.-200 mg
       cryptococ. dis. relapse in AIDS pts., system.candidias., oropharyng.   wks.-3 mnths.  2xdly./400 mg once dly.x8 mnths. Maint. ther.for histoplasmos to
       & oesophag.candidias., candidias. prophylax.in pts.receiv.cytotox.  Contra-indications: Imp.liv.funct., safety in pregn. not est., lac-  prev.relapse usually reqd.in HIV pts.but optim.treatm.& maint. ther.
       chemo and/or radiother.       tat., limit.data on use in childr. theref.not recomm., use in chron./  unknown with stud.ongoing.
       (S4) CAPS, 39/20.2.2/0534, 40/20.2.2/0438  act.liv.dis.not recomm.  Sporotrichos: 100 mg once dly.x 3mnths.
       711530-001: 150 mg, 1, R15,74  Side-effects: Bld.dyscras., CNS effs., psych. disturbs., GI disturbs.,   Paracoccidioidomycos: 100 mg once dly.x6 mnths. Data on effic.
       720045-001: 200 mg, 30, R425,18  hepato-bil.disords., arthralg., myalg., skin reacts.incl. Stevens-John-  of this dos.in AIDS pts.not avail.
       Dosage: Cryptococc.meningit: Adults: Init. 400 mg on 1st day,   son syndr.& tox.epiderm.necrolys., photosens., angioneurot.oed.  Chromomycos: 100-200 mg once dly.x6 mnths.
       then 200-400 mg dly depend.on clinic. respons. Durat.bas.on clinic.  Special precautions: Excret.in breast milk, chron. liv.dysfunct. /  Blastomycos: 100 mg once dly.-200 mg 2xdly./ 400 mg once
       mycologic. respons., usual.8 wks follow.amphotericin B ther. & 10   imp. ren.funct., psorias.  dly.x 6 mnths.
       wks.for monother. Childr. &gt; 4 wks. of age: 6 mg/kg/day - 12 mg/kg/  Drug interactions: Clear.accelerat.by meds. which induc.metabol.,   (S4) ORAL SOL, [P/S] 30/20.2.2/0429. 10 mg/ml.
       day depend.on sever.of infect.  inhib.by meds.which inhib. cytochrom.P-450, inhibits CYP2 D6 -me-  Indications: Oral and/or oesophag.candidosis in HIV seropositive/
       Maint. to prevent.cryptococc.meningit relapse in AIDS pts:   diat. metabol., menstr.disturbs.with OC’s.  AIDS/other immunocompromis. pts., deep fung. infect.prophylax.
       Adults: 100- 200 mg/day.      NOXAFIL, MSD                 where std.ther. consid. inappropr.in haematolog.malign./bone mar-
       System.candidias: Adults: 1st day 400 mg, then 200 mg dly. Dos.  Posaconazole.  row transpl.when pts.expect.to become neutropen.
       may be incr.to 400 mg dly.depend. on clinic.respons. Childr. &gt; 4 wks.   Indications: Oropharyngeal/oesophag. candidias. /candidaem.  827681-003: 150 ml, R1 279,26
       of age: 6 mg/ kg/day - 12 mg/kg/day depend. on sever.of infect. Du-  refract.to other appropr. antifung.agents, invas.aspergillos.re-  Dosage: Oral/oesophag.candidias: 200 mg/day in 1 or2  dos.
       rat.bas.on clinic.& mycologic.respons.  fract.to amphotericin B, fuasarios./zygomycos./ cryptococcos./   x1 wk. Cont.for another wk.if no respons.
       Oropharyngeal candidias: Adults: 50 mg–100 mg dly.for 7-14   chromoblastomycos.& mycetoma dis. refract.to other ther., coc-  Fung.infect.prophylax: 5 mg/kg/day in 2 div. dos.immed.bef.
       days. Sev. immunocompromis. pts. may req.long.treatm.period. Re-  cidioidomycos., prophylax. of invas.fung.infects.in pts.at high risk   cytostat.treatm.& one week bef. transpl.proced.cont.until neu-
       laps.prevent.in AIDS pts: 150 mg once wkly. Childr. &gt; 4 wks.of age:     of such infects.(eg.prolong.neutropen./ haematopoiet. stem cell   trophil recov.
       1st day 6 mg/kg/day, then 3 mg/kg 1 x dly. Treatm. durat. at least 2   transplant receipients).  Contraindications: Pregn., lactat., concom. terfenadine/ astemi-
       wks.to decr.risk of relapse.  (S4) ORAL SUSP, 40 mg/ml. 41/20.3/0719  zole/ bepridil/ mizolastine/ cisapride/dofetilide/quinidine/pimoz-
                          st
       Oesophag.candidias.: Adults: 200 mg on 1  day follow. by 100-200   715049-001: 105 ml, R6 806,21  ide/ levacetylmethadol & sertindole, CYP3A4 metabol. HMG-COA
       mg dly. Dos.up to 400 mg once dly may be used if no clinic.respons.  Dosage: Admin.with meal/240 ml nutrit. supplem. Not to be used   reduct.inhibit.such as simvastin & lovastatin, triazolam & oral mi-
       aft.14 days on low. dos. Treatm.durat.3 wks.& x2 wks.aft.sympt. re-  aft.4 wks.of 1  open. Incr. tot.dly.dos.above 800 mg does not furth.   dazolam, ergot alkaloids, nisoldipine, nifedipine & felodipine, pres.
                                           st
       solv. Childr. &gt; 4 wks. of age:  1st day 6 mg/kg/ day, then 3 mg/kg 1 x   enhanc. expos.  of ventric. dysfunct./CHF hist.except.for treatm.of life-threat./other
       dly. Dos.may be incr.to 12 mg/ kg/day bas.on pts condit & respons.to   Refract.invas.fung.infects./intol.pts with refract. invas.fung.  ser.infects., hypersens. to other azole antifung.agents., no benef.in
       med. Treatm.durat.3 wks.& x2 wks.aft.sympt. resolv.  infects: 400 mg (10 ml) 2xdly. If meal/supplem.cannot be tol.admin.  prophylax. of cryptococc.meningit.in HIV-infect. pts., not stud.in chil-
       Fung.infect.prophylax.in cytotox.chemother. &/ radiat.  dos. 200 mg (5 ml) 4xdly. Ther.durat.bas.on sev.of underly. dis./im-  dr.und.12 yrs & elderly, Oral Sol.also: safety & effic.in cyst.fibros.&
       ther: Adults: 50 mg-400 mg dly.depend. on risk profile. Treatm.  munosuppress.recov.& clinic. respons.  childr.not demonstrat.
       to be init.sev.days bef. neutropen. onset expect.& contin.x7 days   Coccicioidomycos: 400 mg (10 ml) 2xdly. If meal /supplem.cannot   Side effects: Idiosyncrat.hepatit., ser.hepatotox. incl.fatal ac.liv.
                              3
       aft. neutrophil count rises above 1 000 cells/mm . Childr. &gt; 4   be tol.admin.dos.200 mg (5 ml) 4xdly. Ther.durat.bas.on sev.of underly.   fail., headache, GI disturbs., skin reacts.incl. tox.epiderm.necrolys./
       wks.of age: 3-12 mg/kg/day depend.on extent & durat.of the   dis./ immunosuppress.recov.& clinic.respons.  Stev.-John. syndr./ erythema multiforme/exfolat.dermatit./ leuko-
       induc.neutropen.              Oropharyngeal candidias: Load.dos.200 mg (5 ml) once dly on 1   st  cytoclast.vasculit./ac.gen.exanthemat. pustulos., bld.dyscras., ser.
       Vag.candidiasis: Adults: 150 mg as sngl.dos.  day then 100 mg (2,5 ml) once dly.x13 days.  sickn., angioneurot. oed., anaphylax., allerg.reacts., hypertriglyc-
       Recurr.vag.candidias: Adults: 150 mg as sngl. dos. once mnthly.   Refract.oropharyngeal/oesophag.candidias: 400 mg (10 ml)   eridaem., hypokalaem., periph. neuropathy, paraesthes., hypoa-
       Indiv.durat.which range from 4-12 mnths.  2xdly. Ther.durat.bas.on sev.of underly. dis.& clinic.respons.  sethes., dizzin., vis. disturbs.incl.blurr.vis.& diplop., tinnit.trans./
       Candida balanitis: Adults: 150 mg as sngl.dos.  Invas.fung.infect.prophylax: 200 mg (5 ml) 3xdly. Ther.durat.bas.  perman. hear.loss, CHF, pulm.oed., dyspn., pancreatit., dysgeus.,
       Derm.infects.eg.tinea pedis/corporis/cruris /unguium and   on recov.from neutropen./ immunosuppress.  alopec., prurit., photosens., myalg., arthralg., pollakiur., urin.incont.,
       candida infects: Adults: 150 mg as sngl.dos.once wkly.x2-4 wks.  Contraindications: Concom.CYP3A4 substrat. terfenadine/as-  menstr. disords., erect.dysfunct., oed., pyrex., adren. suppress. with
       usuall.but up to 6 wks.may be requir.for tinea pedis.  temizole/cisapride/pimozide & quinidine, concom.ergot alkaloids,   high dos., Caps also: injury, rhinit., URTI, sinusit, Oral Sol.also: fev.,
       Tinea unguium: Treatm.to contin.until nail grown out & replac.  pregn.& lactat. as reproduct.toxic.shown in anim., safety & effic.in   death, cough, taste pervers.
       with uninfect.nail. 3-6 mnths gener. requir.for fingern.re-growth,   childr.bel.13 yrs.not est.  Special precautions: Teratogenicity shown in animals, adeq.
       toenails 6-12 mnths.          Side effects: Naus., headache, neutropen., anorex., dizzin., paraesthes.,   contracept.in women of child-bear. potent. unt.next menstr.per.foll.
       For infts. &lt; 2 wks.of age the above childr.dos. should be used but only   somnol., GI disturbs., dry mouth, elev.LFT, rash, asthen., fatig., pyrex., rare   end of ther., excret. in breast milk, monit.liv.funct., pts.to report S&S
       giv.once every 72 hrs. For infts. aged 2-4 wks.the dos.should be giv.  adren.insuffic.& allerg.reacts., sngl. case of torsade de pointes in pts.  of liv.dysfunct., concom.hepatotox.meds.in rais. liv. enzymes/act.liv.
       every 48 hrs. Max.adult dly dos.not to be exceed.in childr.  with multiple potent.contribut.risk facts., rare haemolyt. uraem.syndr.&   dis./when liv. toxic.exper. with other drugs only init.ther.if benef.ex-
       Contraindications: Other azole antifung. hypersens., co-admin.ter-  thrombot. thrombocytopen. purpura with concom.cyclospor. /tacrolimus.  ceeds hepat. injur.risk, ren.impairm., monit.plasma conc. with con-
       fenadine in pts.receiv. multi. dos.of MYCOREST in dos.≥ 400 mg/day,   Special precautions: Incr.half-life in small number stud.with decr.  com.drugs affect.metab., concom.Ca chann. block.due to incr.CHF
       concom. cisapride/astemizole, avoid in pregn., lactat., multi.dos.ther.  hepat.funct., other azole hypersens., more sev.hepat.reacts.report.  risk, monit.concom. oral anticoags./anti-HIV protease inhibit./cert.
       in pts.with ren.impairm., safety & effic.in childr.not est.for follow.con-  with ser. underly.medic.condits., concom.meds. metabol. through   antineoplast. agents eg.vinca alkaloids, busulphan, docetaxel &
       dits: recurr. vag.candidias./candida balanit./derm. infects. incl.tinea   CYP3A4 known to prolong QTc interv., monit.& correct any electrol.  trimetrexate/ CYP3A4 metabol.Ca chann. block./immunosuppress.
       pedis/corpor./cruris/unguium & derm. candida infects.  imbal.esp. those involv.K+/Mg/Ca lev.  eg.cyclospor./ tacrolimus/ sirolimus/cert.CYP3A4 metabol.HMG-</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page291.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page287.html">287</a>&nbsp;&nbsp;&nbsp;<a href="page288.html">288</a>&nbsp;&nbsp;&nbsp;<a href="page289.html">289</a>&nbsp;&nbsp;&nbsp;<a href="page290.html">290</a>&nbsp;&nbsp;&nbsp;<a href="page291.html">291</a>&nbsp;&nbsp;&nbsp;<a href="page292.html">292</a>&nbsp;&nbsp;&nbsp;<a href="page293.html">293</a>&nbsp;&nbsp;&nbsp;<a href="page294.html">294</a>&nbsp;&nbsp;&nbsp;<a href="page295.html">295</a>&nbsp;&nbsp;&nbsp;<a href="page296.html">296</a>&nbsp;&nbsp;&nbsp;<a href="page297.html">297</a>
             </td>
             <td width="35%"><a href="page293.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page293.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
